Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Avidity Biosciences, Inc. - Common Stock (NQ:RNA)

31.37 -0.77 (-2.40%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jun 13, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 963,544
Open 31.22
Bid (Size) 31.35 (30)
Ask (Size) 31.38 (5)
Prev. Close 32.14
Today's Range 30.93 - 31.73
52wk Range 21.51 - 56.00
Shares Outstanding 54,462,518
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
The Analyst Verdict: Avidity Biosciences In The Eyes Of 12 Experts
Via Benzinga
Avidity Biosciences Touts Encouraging Functional Gains And Biomarker Reductions In Rare Muscular Weakness Disease Trial
Avidity shares early del-brax FSHD data showing improved mobility, strength, and safety; Phase 3 FORWARD trial now underway. 
Via Benzinga

Performance

YTD
+0.6%
+0.6%
1 Month
+5.0%
+5.0%
3 Month
-2.4%
-2.4%
6 Month
-7.1%
-7.1%
1 Year
-18.2%
-18.2%

More News

Read More
12 Analysts Assess Avidity Biosciences: What You Need To Know
Via Benzinga
Why Sarepta Therapeutics And Other Genetics Stocks Just Got A Sizable Boost
Via Investor's Business Daily
Topics Government
Exposures Political Product Safety
Beyond The Numbers: 13 Analysts Discuss Avidity Biosciences Stock
Via Benzinga
Dyne Therapeutics' $4.3 Billion Peak Sales Potential? Analyst Highlights Key Strengths And Risks
Via Benzinga
Avidity Biosciences Stock: A Deep Dive Into Analyst Perspectives (4 Ratings)
Via Benzinga
Analyst Expectations For Avidity Biosciences's Future
Via Benzinga
Forecasting The Future: 13 Analyst Projections For Avidity Biosciences
Via Benzinga
Avidity Biosciences Touts Positive Data From Early-Stage Duchenne Muscular Dystrophy Study Data, FDA Submission Expected By End Of 2025
Via Benzinga
Exposures Product Safety
This S&P Global Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday
Via Benzinga
Topics Stocks
Exposures US Equities
Denali Therapeutics Neurodegenerative Disease Platform Sparks Analyst Optimistic
Via Benzinga
This S&P Global Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday
Via Benzinga
Topics Stocks
Exposures US Equities
What 8 Analyst Ratings Have To Say About Avidity Biosciences
Via Benzinga
Assessing Avidity Biosciences: Insights From 10 Financial Analysts
Via Benzinga
In-Depth Examination Of 10 Analyst Recommendations For Avidity Biosciences
Via Benzinga
Avidity Bio Has Surged 416% This Year — And That's Before Today's 'Game-Changing' News
Via Investor's Business Daily
Evaluating Avidity Biosciences: Insights From 10 Financial Analysts
Via Benzinga
Avidity Biosciences, Up 441%, Nears Another Record High As Dystrophy Space Heats Up
Via Investor's Business Daily
12 Health Care Stocks Moving In Monday's After-Market Session
Via Benzinga
Why Avidity Biosciences Zoomed to a 12% Gain This Week
Via The Motley Fool
Unveiling 7 Analyst Insights On Avidity Biosciences
Via Benzinga
Deep Dive Into Avidity Biosciences Stock: Analyst Perspectives (10 Ratings)
Via Benzinga
Goldman Sachs Bullish On Avidity Biosciences, Cites Scalable RNA Therapeutics Platform For Rare Diseases
Via Benzinga
Fulcrum Therapeutics Upgraded: BofA Debates Pivotal Study Success For Losmapimod In Rare Genetic Muscle Disease
Via Benzinga

Frequently Asked Questions

Is Avidity Biosciences, Inc. - Common Stock publicly traded?
Yes, Avidity Biosciences, Inc. - Common Stock is publicly traded.
What exchange does Avidity Biosciences, Inc. - Common Stock trade on?
Avidity Biosciences, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Avidity Biosciences, Inc. - Common Stock?
The ticker symbol for Avidity Biosciences, Inc. - Common Stock is RNA on the Nasdaq Stock Market
What is the current price of Avidity Biosciences, Inc. - Common Stock?
The current price of Avidity Biosciences, Inc. - Common Stock is 31.37
When was Avidity Biosciences, Inc. - Common Stock last traded?
The last trade of Avidity Biosciences, Inc. - Common Stock was at 06/13/25 04:00 PM ET
What is the market capitalization of Avidity Biosciences, Inc. - Common Stock?
The market capitalization of Avidity Biosciences, Inc. - Common Stock is 1.71B
How many shares of Avidity Biosciences, Inc. - Common Stock are outstanding?
Avidity Biosciences, Inc. - Common Stock has 2B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.